logo-loader

Admedus eyes new revenue stream through supply agreement with 4C Medical Technologies

Published: 13:12 01 Sep 2017 AEST

1504235775_handshake-888542
Admedus is a medical technologies company

Admedus Ltd (ASX:AHZ) has entered into an exclusive supply agreement with 4C Medical Technologies, Inc.

Under the agreement, 4C Medical will add the latest innovation in cardiovascular tissue engineering from Admedus to their novel transcatheter mitral regurgitation treatment technology.

Specifically, the functioning valve apparatus of the 4C implant will utilise tissue processed by Admedus’ clinically superior ADAPT® Tissue Engineering Process for the functioning leaflet component.

This additional key technology optimizes function and durability.

Wayne Paterson, chief executive officer for Admedus, said that he is confident the deal will generate a significant new revenue stream.

"4C Medical has already made significant progress on its development path in the very challenging TMVR space.

"We can now explore potential co-development applications across the full spectrum of transcatheter valves."

Admedus recently beats revenue forecasts for financial year 2017, after delivering a full year sales increase of 58% to $22.3 million.

READ NOW: Admedus beats revenue forecasts

Anteris talks market superiority of its biomimetic TAVR valve

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson speaks with Proactive after the successful completion of enrolment for the company’s early feasibility study (EFS) to evaluate DurAVR™ THV. This unique device represents a new class of biomimetic valve and stands as the world's...

on 31/10/23